Cytokeratin 8 Level in Age-related Macular Degeneration

Sponsor
Gangnam Severance Hospital
Study ID
NCT02707575
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.

Study Details

The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (AMD) before therapy with intravitreal Ranibizumab, and identify associations with visual and anatomical outcome after treatment.

Key Dates

First listed
Mar 14, 2016
Start date
Apr 26, 2016
Status verified
Dec 2020
Primary completion
Mar 12, 2018
Completion
Apr 23, 2018

Study Design

Enrollment
58 participants (actual)

Arms

  • Arm: Ranibizumab
    Intravitreal Ranibizumab

Primary Outcome Measure

The changes in the Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity [ Time Frame: From baseline to one month after three monthly consecutive ranibizumab injection ]

Related Studies